Respiratory syncytial virusinfection and novel interventions


Annefleur C. Langedijk and Louis J. Bont

The large global burden of respiratory syncytial virus (RSV) respiratory
tract infections in young children and older adults has gained
increased recognition in recent years. Recent discoveries regarding
the neutralization-specifc viral epitopes of the pre-fusion RSV
glycoprotein have led to a shift from empirical to structure-based design
of RSV therapeutics, and controlled human infection model studies
have provided early-stage proof of concept for novel RSV monoclonal
antibodies, vaccines and antiviral drugs.